Should I buy or sell Verona Pharma stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRNA shares. View VRNA analyst ratings or view top-rated stocks .

What is Verona Pharma's stock price target for 2024?

4 brokerages have issued 12 month target prices for Verona Pharma's stock. Their VRNA share price targets range from $32.00 to $36.00. On average, they predict the company's share price to reach $33.60 in the next twelve months. This suggests a possible upside of 113.7% from the stock's current price. View analysts price targets for VRNA or view top-rated stocks among Wall Street analysts .

How have VRNA shares performed in 2024?

Verona Pharma's stock was trading at $19.88 at the start of the year. Since then, VRNA stock has decreased by 20.9% and is now trading at $15.72. View the best growth stocks for 2024 here .

When is Verona Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our VRNA earnings forecast .

How were Verona Pharma's earnings last quarter?

Verona Pharma plc (NASDAQ:VRNA) posted its quarterly earnings data on Thursday, February, 29th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.07.

What ETF holds Verona Pharma's stock?

ALPS Medical Breakthroughs ETF holds 56,560 shares of VRNA stock, representing 0.83% of its portfolio.

What other stocks do shareholders of Verona Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE) , Dynavax Technologies (DVAX) , Trevena (TRVN) , Pfizer (PFE) , Citius Pharmaceuticals (CTXR) , electroCore (ECOR) , Inovio Pharmaceuticals (INO) , SCYNEXIS (SCYX) , VBI Vaccines (VBIV) and Vaxart (VXRT) .

When did Verona Pharma IPO?

Verona Pharma (VRNA) raised $61 million in an initial public offering on Thursday, April 27th 2017. The company issued 4,500,000 shares at $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

Who are Verona Pharma's major shareholders?

Verona Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.08%). Insiders that own company stock include Anders Ullman , Claire Poll , David R Ebsworth , David Zaccardelli , Kathleen A Rickard , Lisa Deschamps , Mark W Hahn , Martin Edwards , Orbimed Advisors Llc and Patrick John Finn . View institutional ownership trends .

How do I buy shares of Verona Pharma?

Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VRNA

Verona Pharma (VRNA) Stock Price, News & Analysis

→ The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad)

Free VRNA Stock Alerts

$15.72

-0.38 (-2.36%)

(As of 04/19/2024 ET)

Compare

Today's Range: $15.43
▼
$16.20
50-Day Range: $15.30
▼
$18.19
52-Week Range: $11.83
▼
$23.81

Volume: 717,952 shs
Average Volume: 501,106 shs
Market Capitalization: $1.27 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $33.60

Get Verona Pharma alerts:

Verona Pharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 113.7% Upside
$33.60 Price Target
Short Interest: Bearish
8.12% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.53
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.32) to ($0.85) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.11 out of 5 stars

Medical Sector

760th out of 911 stocks

Pharmaceutical Preparations Industry

336th out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
Verona Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Verona Pharma has only been the subject of 3 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
8.12% of the outstanding shares of Verona Pharma have been sold short.
Short Interest Ratio / Days to Cover
Verona Pharma has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Verona Pharma has recently increased by 2.50%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Verona Pharma does not currently pay a dividend.
Dividend Growth
Verona Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VRNA.

2.0

News and Social Media Coverage

News Sentiment
Verona Pharma has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Verona Pharma this week, compared to 2 articles on an average week.
Search Interest
Only 4 people have searched for VRNA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Verona Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Verona Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.80% of the stock of Verona Pharma is held by insiders.
Percentage Held by Institutions
85.88% of the stock of Verona Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Verona Pharma are expected to grow in the coming year, from ($1.32) to ($0.85) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Verona Pharma is -22.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Verona Pharma is -22.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Verona Pharma has a P/B Ratio of 5.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Weiss Ratings

The only accurate crypto trading system I know …

Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.

Here's what our expert says you should buy before April 14.

About Verona Pharma Stock (NASDAQ:VRNA)

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

VRNA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VRNA Stock News Headlines

April 17, 2024 | americanbankingnews.com

Verona Pharma (NASDAQ:VRNA) Price Target Increased to $36.00 by Analysts at Piper Sandler

April 17, 2024 | americanbankingnews.com

Verona Pharma (NASDAQ:VRNA) Trading 3.7% Higher After Analyst Upgrade

April 19, 2024 | Banyan Hill Publishing (Ad)

The Best AI Stock to Own in the World Today is Trading for Just $25

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

March 16, 2024 | finance.yahoo.com

VRNA Apr 2024 17.500 call

March 16, 2024 | finance.yahoo.com

VRNA Apr 2024 15.000 call

March 4, 2024 | globenewswire.com

Andrew Fisher Joins Verona Pharma as General Counsel

March 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed: Verona Pharma’s Promising Future with Ensifentrine and Expanding R&D Pipeline

March 1, 2024 | finance.yahoo.com

Verona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcript

April 19, 2024 | Banyan Hill Publishing (Ad)

The Best AI Stock to Own in the World Today is Trading for Just $25

March 1, 2024 | fool.com

3 Healthcare Stocks That Have Outperformed Nvidia Since 2022

February 29, 2024 | seekingalpha.com

Verona Pharma plc 2023 Q4 - Results - Earnings Call Presentation

February 29, 2024 | finanznachrichten.de

Verona Pharma plc: Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

February 29, 2024 | finance.yahoo.com

Verona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial Results

February 29, 2024 | globenewswire.com

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

February 28, 2024 | markets.businessinsider.com

Verona Pharma earnings preview: what to expect

February 25, 2024 | finance.yahoo.com

When Will Verona Pharma plc (NASDAQ:VRNA) Turn A Profit?

February 25, 2024 | wsj.com

Verona Pharma PLC ADR

February 17, 2024 | finance.yahoo.com

VRNA Mar 2024 15.000 put

February 17, 2024 | finance.yahoo.com

VRNA Jun 2024 30.000 call

February 15, 2024 | seekingalpha.com

Verona Pharma: A Few Points From The Bull And Bear Case

February 15, 2024 | finance.yahoo.com

Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

February 15, 2024 | globenewswire.com

Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

January 23, 2024 | investing.com

Verona Pharma PLC ADR (VRNA)

January 19, 2024 | seekingalpha.com

Verona Pharma: Upcoming PDUFA, Expired Patent, Strong Data

January 15, 2024 | finance.yahoo.com

Verona Pharma plc's (NASDAQ:VRNA) latest 11% decline adds to one-year losses, institutional investors may consider drastic measures

January 11, 2024 | markets.businessinsider.com

Piper Sandler Reaffirms Their Buy Rating on Verona Pharma (VRNA)

January 3, 2024 | finance.yahoo.com

Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference

See More Headlines

Receive VRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:VRNA
CUSIP: N/A
CIK: 1657312
Web: www.veronapharma.com
Phone: 011-44-0-2032834200
Fax: N/A
Employees: 79
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $33.60
High Stock Price Target: $36.00
Low Stock Price Target: $32.00
Potential Upside/Downside: +110.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.69)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-54,370,000.00
Net Margins: N/A
Pretax Margin: -10,946.07%
Return on Equity: -20.47%
Return on Assets: -17.72%

Debt

Debt-to-Equity Ratio: 0.20
Current Ratio: 33.33
Quick Ratio: 33.33

Sales & Book Value

Annual Sales: $460,000.00
Price / Sales: 2,811.13
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.10 per share
Price / Book: 5.16

Miscellaneous

Outstanding Shares: 80,820,000
Free Float: 76,937,000
Market Cap: $1.29 billion
Optionable: Optionable
Beta: 0.40

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. David S. Zaccardelli Pharm.D. (Age 60)
President, CEO & Executive Director
Comp: $1.27M
Mr. Mark W. Hahn (Age 61)
Chief Financial Officer
Comp: $858.29k
Dr. Kathleen A. Rickard M.D. (Age 66)
Chief Medical Officer
Comp: $650.83k
Mr. Andrew Fisher (Age 54)
General Counsel
Ms. Victoria Stewart
Director of Communications
Mr. Matthew Casbon
VP of Sales, Marketing & Training
Ms. Ostra Jewell
Senior Vice President of Human Resources
Dr. Tara Rheault M.P.H. (Age 47)
Ph.D., Chief Development Officer
Mr. Christopher Martin
Chief Commercial Officer
Ms. Caroline Diaz
Senior Vice President of Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VRNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Verona Pharma stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRNA shares.
View VRNA analyst ratings or view top-rated stocks.
What is Verona Pharma's stock price target for 2024?: 4 brokerages have issued 12 month target prices for Verona Pharma's stock. Their VRNA share price targets range from $32.00 to $36.00. On average, they predict the company's share price to reach $33.60 in the next twelve months. This suggests a possible upside of 113.7% from the stock's current price.
View analysts price targets for VRNA or view top-rated stocks among Wall Street analysts.
How have VRNA shares performed in 2024?: Verona Pharma's stock was trading at $19.88 at the start of the year. Since then, VRNA stock has decreased by 20.9% and is now trading at $15.72.
View the best growth stocks for 2024 here.
When is Verona Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our VRNA earnings forecast.
How were Verona Pharma's earnings last quarter?: Verona Pharma plc (NASDAQ:VRNA) posted its quarterly earnings data on Thursday, February, 29th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.07.
What ETF holds Verona Pharma's stock?: ALPS Medical Breakthroughs ETF holds 56,560 shares of VRNA stock, representing 0.83% of its portfolio.

What other stocks do shareholders of Verona Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Vaxart (VXRT).
When did Verona Pharma IPO?: Verona Pharma (VRNA) raised $61 million in an initial public offering on Thursday, April 27th 2017. The company issued 4,500,000 shares at $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.
Who are Verona Pharma's major shareholders?: Verona Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.08%). Insiders that own company stock include Anders Ullman, Claire Poll, David R Ebsworth, David Zaccardelli, Kathleen A Rickard, Lisa Deschamps, Mark W Hahn, Martin Edwards, Orbimed Advisors Llc and Patrick John Finn.
View institutional ownership trends.
How do I buy shares of Verona Pharma?: Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VRNA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial